

INFORMATION ONLY

Obizur® Temporary Labelling Update

Customer Letter # 2020-38

2020-08-14

Dear Colleagues:

Due to an increased demand for Obizur® 500 units [Antihemophilic Factor (Recombinant), Porcine Sequence], Health Canada has approved Takeda Canada to temporarily import and ship USA labelled Obizur® product lot VN22501AL into Canada to meet immediate patient needs.

The USA Obizur® product is similar to the Canadian product with the exception of the labelling. Please see the attached letter from Takeda Canada for product details.

Canadian labelled Obizur® product is expected to be available by mid September 2020.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier

Director, Plasma Protein Products Formulary Program